WILMINGTON,aaiPharma has won FDA approval to begin marketing Calcitriol Injection, a liquid, injectable vitamin D product for the treatment of kidney dialysis patients with abnormally low levels of calcium.

The market for such drugs is $300 million, and aaiPharma believes Calcitriol will fare well since it is administered in an easier fashion.

After getting the approval, aaiPharma (Nasdaq: AAII) increased its financial guidance for 2003 by $5-$10 million, to between $285 million and $290 million.

aaiPharma: www.aaipharma.com